Loading asset research
Galectin Therapeutics Inc. Common Stock
GALTNasdaq · USD · StocksQuote as of · Exchange session not verified$3.90
-1.52%
Today
GALT
Loading 1D prices…
Market cap
$399.4M
Volume
124.6K
52w high
$7.1352w low
$2.03Company profile
Galectin Therapeutics Inc. Common Stock
Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in drug development to create new therapies for fibrotic disease and cancer. The company's lead product candidate is belapectin (GR-MD-02), a galectin-3 inhibitor, which is in a Phase 2 clinical study in MASH patients with advanced fibrosis and a second Phase 2b clinical trial in MASH patients with compensated cirrhosis and portal hypertension. It has a joint venture co-owned by SBH Sciences, Inc. to research and develop small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.
Sector
Health Care
Industry
Pharmaceutical Preparations
Exchange
Nasdaq
Display currency
USD
Location
Norcross, GA, United States
Employees
9
Fiscal year end
1231
CIK
1133416
Session & valuation
Open$3.93
Previous close$3.96
Day high$3.99
Day low$3.86
30-day avg. volume320.3K
Outstanding shares100.8M
Diluted EPS-$0.48
Latest annual period
P/E (trailing)-8.13
P/E (forward)-2.36
Price / book-1.89
Beta0.39
Dividend yield—
Deterministic peer set
Companies with SEC SIC 2834
Exact regulatory industry matches, ranked by nearest market capitalization.
| Company | Market cap | Revenue | Net margin | Diluted EPS | Today | Consensus |
|---|---|---|---|---|---|---|
| ARCTArcturus Therapeutics Holdings Inc. Common Stock | $401.3M | $82M | -80.19% | -$2.40 | -1.84% | Buy |
| TTRXTurn Therapeutics Inc. Common Stock | $402.7M | $0.00 | — | -$0.12 | -6.60% | Buy |
| IRDOpus Genetics Inc. Common Stock | $405.2M | $14.2M | -349.33% | -$0.80 | -2.05% | Buy |
| RLMDRelmada Therapeutics Inc. Common Stock | $406.4M | $0.00 | — | -$1.45 | +0.66% | Buy |
| SPRYARS Pharmaceuticals Inc. Common Stock | $412.7M | $84.3M | -203.25% | -$1.74 | -2.05% | Buy |